Ann Renucci, MD
Ophthalmology · Grand Rapids, MINPI 1124091087
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (43.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Biotissue Holdings Inc. accounts for 70.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $1,038 and has fallen 98.3% since, to $17 in 2025.
Across 12 payments — averaging $184.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$2K
- Rxsight Inc$315
- Hoffmann-la Roche Limited$148
- Alcon$142
- Optos, Inc.$45
What the payments were for
- Consulting fees$43119%
- Travel & lodging$96143%
- Food & beverage$78135%
- Entertainment$452%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 7 | $1,569 |
| Rxsight Inc | 1 | $315 |
| Hoffmann-la Roche Limited | 1 | $148 |
| Alcon | 2 | $142 |
| Optos, Inc. | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,219 in reported general payments places this provider in the 65th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 22 | $21,773 |
| Prednisolone Acetate | 340 | $9,582 |
| Fluorometholone | 60 | $5,948 |
| ValacyclovirValacyclovir Hcl | 34 | $1,857 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 19 | $648 |
| Latanoprost | 39 | $644 |
| Timolol Maleate | 30 | $371 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 43 | $323 |
| Ketorolac Tromethamine | 17 | $211 |
| Ofloxacin | 11 | $142 |
| ErythromycinErythromycin Base | 11 | $128 |
| Doxycycline Hyclate | 13 | $65 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 28 | $56 |
| Diazepam | 19 | $16 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Grand Rapids
- Scott WesthouseGrand Rapids$138K
- Austen KnappGrand Rapids$16K
- Marcus MuallemGrand Rapids$15K
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
- Jason MillerAnn Arbor$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.